Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1195-1204

  Guay, David R P ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY 4 [2 [2 (3,5 DIMETHYL 1 PIPERIDINYL)NICOTINAMIDO]ETHYL]BENZOIC ACID; ACARBOSE; ADENOSINE TRIPHOSPHATE; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BENZOIC ACID DERIVATIVE; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CORTICOSTEROID; CYTOCHROME P450; DIGOXIN; ESTROGEN; GLIBENCLAMIDE; ISONIAZID; METFORMIN; MIGLITOL; MITIGLINIDE; NATEGLINIDE; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHENOTHIAZINE DERIVATIVE; REPAGLINIDE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ARTICLE; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; POSTPRANDIAL STATE;

CARBAMATES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PIPERIDINES; TREATMENT OUTCOME;

EID: 0031726609     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ribes G, Trimble ER, Wollheim CB, Blayac JP, Loubatieres-Mariani MM. Stimulation of pancreatic polypeptide secretion in the dog by hypoglycemic agent HB699. Am J Physiol 1983;244:E380-4.
2. Garrino MG, Schmeer W, Nenquin M, Meissner HP, Henquin JC. Mechanism of the stimulation of insulin release in vitro by HB699, a benzoic acid derivative similar to the non-sulfonylurea moiety of glibenclamide. Diabetologia 1985;28: 697-703.
3. Panten U, Burgfeld J, Goerke F, et al. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochem Pharmacol 1989;38:1217-29.
4. Novo Nordisk Pharmaceuticals. Prandin (repaglinide) package insert. Princeton, NJ;1997.
5. Lins L, Brasseur R, Malaisse WJ. Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family. Biochem Pharmacol 1995;50:1879-84.
6. Kofod H, Fuhlendorff J. Repaglinide compared to glibenclamide in isolated mouse islet by perfusion [abstr]. Diabetologia 1995;38(suppl 1):A195.
7. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Insulinotropic action of meglitinide analogs: concentration-response relationship and nutrient dependency. Diabetes Res 1994;27:81-7.
8. Mark M, Grell W. Hypoglycemic effects of the novel antidiabetic agent repaglinide in rats and dogs. Br J Pharmacol 1997;121:1597-1604.
9. Ladriere L, Malaisse-Lagae F, Fuhlendorff J, Malaisse WJ. Repaglinide, glibenclamide and glimepiride administration to normal and hereditary diabetes rats. Eur J Pharmacol 1997;335:227-34.
10. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium channels and cytosolic calcium levels in β TC3 cells and rat pancreatic beta cells. Diabetologia 1995;38:1025-32.
11. + concentrations. Pharmacol Res 1995;32:111-14.
12. Frokjaer-Jensen J, Kofod H, Godtfredsen SE. Mechanism of action of AG-EE 623 ZW, a novel insulinotropic agent [abstr]. Diabetologia 1992;35(suppl 1):A116.
13. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Ionophoretic activity of meglitinide analogues. Diabetes Res 1994;27:61-71.
14. Fuhlendorff J, Shymko R, Carr RD, Kofod H. Characterization of the binding sites for the novel anti-hyperglycemic drug, repaglinide [abstr]. Diabetes 1995;44(suppl 1):231A.
15. Fuhlendorff J, Carr R, Kofod H, Rorsman P. The mechanism of action of repaglinide differs to sulphonylureas in murine beta cells [abstr]. Pharmacol Res 1995;31:32.
16. Fuhlendorff J. Molecular identification of a specific binding site (36 kDa) for repaglinide [abstr]. Diabetes 1998;47(suppl 1):A416.
17. Wolffenbuttel BHR, Nijst L, Sels JPJE, Menheere PPCA, Muller PG, Nieuwenhuijzen Kruseman AC. Effects of a new oral hypoglycemic agent, repaglinide, on metabolic control in sulfonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 1993;45:113-16.
18. Schwartz SL, Strange P, and the Repaglinide Study Group. Repaglinide does not accumulate in patients with type 2 diabetes [abstr]. Diabetes 1998;47(suppl 1):A357.
19. Hatorp V, Hang-Pihale G. A comparison of the pharmacokinetics of repaglinide in healthy subjects with that in subjects with chronic liver disease [abstr]. Diabetes 1998;47(suppl 1):A356.
20. Marbury TC, Hatorp V. Pharmacokinetics of repaglinide after single and multiple doses in patients with renal impairment compared with normal healthy volunteers [abstr]. Diabetes 1998;47(suppl 1):A357.
21. Ampudia-Blasco FJ, Heinemann L, Bender R, et al. Comparative dose-related time-action profiles of glibenclamide and a new non-sulfonylurea drug, AG-EE 623 ZW, during euglycemic clamp in healthy subjects. Diabetologia 1994;37:703-7.
22. Parentesis GP, Damsbo P, Muller PG, Gawrylewski H, Bhattacharyya H. Single dose pharmacokinetics and pharmacodynamics of repaglinide in type 2 diabetic patients [abstr]. J Clin Pharmacol 1994;34:1021.
23. Damsbo P, Andersen PH, Lund S, Porksen N. Improved glycaemic control with repaglinide in NIDDM with 3 times daily meal related dosing [abstr]. Diabetes 1997;46(suppl 1):34A.
24. Van Gaal LF, Van Acker KL, Damsbo P, DeLeeuw IH. Metabolic effects of repaglinide, a new oral hypoglycemic agent in therapy-naive type 2 diabetics [abstr]. Diabetologia 1995;38(suppl 1):A43.
25. Goldberg RB, Brodows RG, Damsbo P, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes [abstr]. Diabetes 1998;47(suppl 1):A98.
26. Schwartz SL, Goldberg RB, Strange P, et al. Repaglinide in type 2 diabetes: a randomized, double-blind, placebo-controlled, dose-response study [abstr]. Diabetes 1998; 47(suppl 1):A98.
27. Berger S, Strange P, and the Repaglinide Study Group. Repaglinide, a novel oral hypoglycemic agent in type 2 diabetes: a randomized, placebo-controlled, double-blind, fixed dose study [abstr]. Diabetes 1998;47(suppl 1):A18.
28. Profozic V, Babic D, Renar I, Rupprecht E, Skrabalo Z, Metelko Z. Benzoic acid derivative hypoglycemic activity in non-insulin dependent diabetic patients [abstr]. Diabetologia 1993;36(suppl 1):A183.
29. Landgraf R, Bilo H. Repaglinide vs. glibenclamide: a 14-week efficacy and safety comparison [abstr]. Diabetes 1997;46(suppl 1):162A.
30. Marbury TC, Strange P, and the Repaglinide Study Group Multicenter, randomized comparison of the therapeutic effects of long-term use of repaglinide with glyburide in type 2 diabetes [abstr]. Diabetes 1998;47(suppl 1):A75.
31. Moses R, Slobodniuk R, Donnelly T, et al. Additional treatment with repaglinide provides significant improvement in glycaemic control in NIDDM patients poorly controlled on metformin [abstr]. Diabetes 1997;46(suppl 1):93A.
32. Marbury TC, Hatorp V, Damsbo P, Muller PG. Repaglinide can be given in a flexible preprandial dosing regimen in patients with type 2 diabetes [abstr]. Diabetes 1998;47(suppl 1):A355.
33. Tronier M, Marbury TC, Damsbo P, Windfeld K. A new oral hypoglycemic agent, repaglinide minimizes risk of hypoglycemia in well-controlled NIDDM patients [abstr]. Diabetologia 1995;38(suppl 1):A195.
34. Michalets EL. Update: clinically significant cytochrome P-450 interactions. Pharmacotherapy 1998;18:84-112.
35. Meinert CL, Knatterud GL, Prout TE, Klint CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19(suppl 2):789-830.